Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)

被引：0
|
作者：
Quach, Hang [1 ]
Prince, Miles H. [1 ]
Mileshkin, Linda [1 ]
Seymour, John F. [1 ]
Westerman, David [1 ,2 ]
Milner, Alvin D. [3 ]
机构：
[1] Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2718.2718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2718
引用
收藏
页码：798A / 798A
页数：1
相关论文
共 50 条
  • [21] Pomalidomide Monotherapy for Relapsed Myeloma Is Associated with Excellent Responses and Prolonged Progression Free and Overall Survival
    Streetly, Matthew
    Stewart, Orla
    Gyertson, Kylie
    Kazmi, Majid A.
    Schey, Steve
    BLOOD, 2009, 114 (22) : 1492 - 1492
  • [22] Dose-dependent effect of thalidomide (Thal) on overall survival (OS) in relapsed and refractory multiple myeloma (MM).
    Neben, K
    Moehler, TM
    Benner, A
    Kraemer, A
    Ho, AD
    Goldschmidt, H
    BLOOD, 2001, 98 (11) : 163A - 163A
  • [23] African American relapsed/refractory multiple myeloma patients have a progression free survival benefit with selinexor treatment in the STORM study
    Cole, Craig
    Opalikhin, Anne
    McCartney, Matthew
    Heideman, Caroline
    Pentapati, Swetha
    Wang, Ling
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S168 - S169
  • [24] Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations
    Johnson, David C.
    Gregory, Walter M.
    Dickens, Nicholas J.
    Walker, Brian A.
    Szubert, Alex J.
    Davies, Faith E.
    Durie, Brian G. M.
    Van Ness, Brian G.
    Morgan, Gareth J.
    BLOOD, 2009, 114 (22) : 177 - 177
  • [25] A phase II trial of thalidomide in the treatment of relapsed multiple myeloma (MM) with laboratory correlative studies.
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Geyer, S
    Wellik, L
    Hayman, S
    Lust, JA
    Kyle, RA
    Greipp, PR
    Gertz, MA
    Witzig, TE
    BLOOD, 2000, 96 (11) : 168A - 168A
  • [26] Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide
    Teresa Cibeira, Maria
    Fernandez de Larrea, Carlos
    Navarro, Alfons
    Diaz, Tania
    Fuster, Dolors
    Tovar, Natalia
    Rosinol, Laura
    Monzo, Mariano
    Blade, Joan
    LEUKEMIA RESEARCH, 2011, 35 (09) : 1178 - 1183
  • [27] Osteoblastic activation and response to VELCADE® in patients with relapsed/refractory multiple myeloma (MM).
    Zangari, M
    Lee, CK
    Barlogie, B
    Najarian, K
    Kang, SH
    Yaccoby, S
    Esseltine, D
    Stover, JM
    Tricot, GJ
    BLOOD, 2004, 104 (11) : 309B - 309B
  • [28] Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
    Yang, Tung-Lung
    Lin, Chin
    Ho, Ching-Liang
    Huang, Tzu-Chuan
    Wu, Yi-Ying
    Jhou, Hong-Jie
    Chen, Po-Huang
    Lee, Cho-Hao
    LIFE-BASEL, 2023, 13 (12):
  • [29] DARATUMUMAB SIGNIFICANTLY IMPROVED PROGRESSION-FREE SURVIVAL IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA
    Katalinic, D.
    HAEMATOLOGICA, 2017, 102 : 526 - 527
  • [30] Thalidomide as anti-angiogenesis treatment in patients with chemotherapy resistant multiple myeloma (MM).
    Wu, K
    Schaafsma, MR
    Smit, WM
    Neef, C
    Richel, DJ
    BLOOD, 1999, 94 (10) : 316B - 316B
12345